Key FDA reform bills could be undermined by pre-emption clause
This article was originally published in Clinica
Executive Summary
US House Democrats drafted a package of Food and Drug Administration reform bills late last week that included a few tiny lines that caused a big fuss at a hearing on Tuesday June 12. Those lines would prohibit FDA law from pre-empting state court damage claims that opponents say could potentially jeopardise passage, writes April Fulton.